PD-L1 expression in pre-treatment tumor or immune cells is upregulated as a consequence of proinflammatory cytokine interferon-gamma (IFN-γ) released from T cells activation, presumably by tumor-associated antigens within the microenvironment (44). The gene discussed is CD274; the disease is neoplasm.